Selected article for: "inactivated vaccine and suitable candidate"
Author: Saha, Rudra P.; Sharma, Ashish Ranjan; Singh, Manoj K.; Samanta, Saikat; Bhakta, Swarnav; Mandal, Snehasish; Bhattacharya, Manojit; Lee, Sang-Soo; Chakraborty, Chiranjib
Title: Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
  • Cord-id: 0gzjrbm8
  • Document date: 2020_8_19
    • ID: 0gzjrbm8
    Snippet: As the COVID-19 is still growing throughout the globe, a thorough investigation into the specific immunopathology of SARS-CoV-2, its interaction with the host immune system and pathogen evasion mechanism may provide a clear picture of how the pathogen can breach the host immune defenses in elderly patients and patients with comorbid conditions. Such studies will also reveal the underlying mechanism of how children and young patients can withstand the disease better. The study of the immune defen
    Document: As the COVID-19 is still growing throughout the globe, a thorough investigation into the specific immunopathology of SARS-CoV-2, its interaction with the host immune system and pathogen evasion mechanism may provide a clear picture of how the pathogen can breach the host immune defenses in elderly patients and patients with comorbid conditions. Such studies will also reveal the underlying mechanism of how children and young patients can withstand the disease better. The study of the immune defense mechanisms and the prolonged immune memory from patients population with convalescent plasma may help in designing a suitable vaccine candidate not only for the current outbreak but also for similar outbreaks in the future. The vital drug candidates, which are being tested as potential vaccines or therapeutics against COVID-19, include live attenuated vaccine, inactivated or killed vaccine, subunit vaccine, antibodies, interferon treatment, repurposing existing drugs, and nucleic acid-based vaccines. Several organizations around the world have fast-tracked the development of a COVID-19 vaccine, and some drugs already went to phase III of clinical trials. Hence, here, we have tried to take a quick glimpse of the development stages of vaccines or therapeutic approaches to treat this deadly disease.

    Search related documents:
    Co phrase search for related documents
    • acid base vaccine and acute respiratory syndrome: 1
    • activate cell and acute ards respiratory distress syndrome: 1
    • activate cell and acute respiratory distress syndrome: 1
    • activate cell and acute respiratory distress syndrome ards: 1
    • activate cell and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • activate cell and adaptive immune response: 1, 2, 3
    • activate cell and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • active form and acute ards respiratory distress syndrome: 1
    • active form and acute respiratory distress syndrome: 1
    • active form and acute respiratory distress syndrome ards: 1
    • active form and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active form and adaptive immune response: 1, 2, 3
    • active form and adaptive immunity: 1, 2
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory distress syndrome ards and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11